Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Candel Therapeutics, Inc. - Common Stock
(NQ:
CADL
)
4.790
-0.125 (-2.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Candel Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 03, 2025
Via
Benzinga
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
September 02, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
August 28, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Reports 88 Percent Q2 Loss Drop
August 14, 2025
Via
The Motley Fool
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
July 30, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
July 24, 2025
From
Candel Therapeutics
Via
GlobeNewswire
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 16, 2025
Via
Benzinga
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
July 09, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
June 24, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
June 23, 2025
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
June 06, 2025
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy
May 28, 2025
Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.
Via
Stocktwits
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
May 28, 2025
Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results.
Via
Benzinga
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
May 28, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
May 27, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
May 22, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish
May 13, 2025
The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.
Via
Stocktwits
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 13, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at Upcoming Investor Conferences
May 06, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Top movers in Wednesday's after hours session
April 23, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 23, 2025
Via
Benzinga
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
April 23, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
April 01, 2025
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
March 27, 2025
Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.
Via
Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On?
March 27, 2025
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.
Via
Benzinga
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
March 27, 2025
The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.
Via
Stocktwits
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
March 20, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
March 26, 2025
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
March 18, 2025
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.